FDA Approval: Adjuvant Alectinib for Resected NSCLC Lung Cancer Considered
-
- Science
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
38 min